Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 3/20 | 0.70 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.70 |
| ▸ | MEN1 | O00255 | 5/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.60 |
| ▸ | MAPT | P10636 | 3/20 | 0.60 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.60 |
| ▸ | POLB | P06746 | 2/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9627281 | 0.89 | HTT (0.57) | HTTSMN1; SMN2MEN1KMT2AL3MBTL1 | |
| SCHEMBL13695046 | 0.85 | HTT (0.70) | HTTSMN1; SMN2MEN1KMT2AL3MBTL1 | |
| SCHEMBL9781238 | 0.84 | HTT (0.68) | HTTSMN1; SMN2MEN1KMT2AL3MBTL1 | |
| SCHEMBL19505658 | 0.82 | HTT (1.00) | HTTSMN1; SMN2MEN1KMT2AL3MBTL1 | |
| SCHEMBL178622 | 0.81 | SLC6A4 (0.60) | MEN1KMT2AL3MBTL1CYP2D6CYP2C19 | |
| SCHEMBL896368 | 0.81 | SLC6A4 (0.60) | MEN1KMT2AL3MBTL1CYP2D6CYP2C19 | |
| SCHEMBL879606 | 0.80 | HTT (0.62) | HTTSMN1; SMN2MEN1KMT2AL3MBTL1 | |
| SCHEMBL9627122 | 0.80 | MAOB (0.62) | HTTSMN1; SMN2MEN1KMT2AL3MBTL1 | |
| SCHEMBL19498809 | 0.80 | HTT (0.82) | HTTSMN1; SMN2MEN1KMT2AL3MBTL1 | |
| Hydrochloric Acid SCHEMBL29410112 | 0.79 | SLC6A4 (0.58) | MEN1KMT2AL3MBTL1CYP2D6CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4460492-A1 | COMPOUNDS CONTAINING A HYDROXYPHENYL MOIETY AND THEIR USE | (INSERM) Institut National de la Santé et de la Recherche Médicale (FR) | 2024-11-13 | — | — | EP | disclosed |
| WO-2023131677-A1 | COMPOUNDS CONTAINING A HYDROXYPHENYL MOIETY AND THEIR USE | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2023-07-13 | — | — | WO | disclosed |
| WO-2023131677-A1 | COMPOUNDS CONTAINING A HYDROXYPHENYL MOIETY AND THEIR USE | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2023-07-13 | — | — | WO | disclosed |
| US-8883824-B2 | 3-(4-aminophenyl)-2-furancarboxylic acid derivative and pharmaceutically acceptable salt thereof | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2014-11-11 | — | — | US | disclosed |
| US-20120059012-A1 | 3-(4-AMINOPHENYL)-2-FURANCARBOXYLIC ACID DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2012-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120059012-A1 | 3-(4-AMINOPHENYL)-2-FURANCARBOXYLIC ACID DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | ACSL3, SLCO4C1, SLC38A7 | HTT 3325/4885SMN1; SMN2 2373/4885MEN1 945/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.